Exdensur Approved in the UK for Treatment of Asthma With Type 2 Inflammation and Chronic Rhinosinusitis With Nasal Polyps
December 16, 2025
December 16, 2025
LONDON, England, Dec. 16 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 15, 2025:
* * *
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
* First and only ultra-long-acting biologic with twice-yearly dosing to treat respiratory diseases
* UK approval based on data from the SWIFT and ANCHOR phase III tr . . .
* * *
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
* First and only ultra-long-acting biologic with twice-yearly dosing to treat respiratory diseases
* UK approval based on data from the SWIFT and ANCHOR phase III tr . . .